Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 3820-3832

  Patel, Gautam ^a   Karver, Caitlin E ^a   Behera, Ranjan ^b   Guyett, Paul J ^b   Sullenberger, Catherine ^b   Edwards, Peter ^a   Roncal, Norma E ^c   Mensa Wilmot, Kojo ^b   Pollastri, Michael P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; CANERTINIB; LAPATINIB; LEAD; NEU 617; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL DIVISION; CONTROLLED STUDY; CYTOKINESIS; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; KINETOPLAST; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMIASIS;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COLORING AGENTS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; INDICATORS AND REAGENTS; MORPHOLINES; NEGLECTED DISEASES; PHOSPHOTRANSFERASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLIUM SALTS; THIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 84878042492     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400349k     Document Type: Article

References (51)

1. Uniting to Combat NTDs Homepage; www.unitingtocombatntds.org, 2013; (accessed 12 April 2013).
2. Pollastri, M. P.; Campbell, R. K. Target repurposing for neglected diseases Future Med. Chem. 2011, 3, 1307-1315
3. Gould, M. K.; de Koning, H. P. Cyclic-nucleotide signalling in protozoa FEMS Microbiol. Rev. 2011, 35, 515-541
4. Parsons, M.; Worthey, E. A.; Ward, P. N.; Mottram, J. C. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi BMC Genomics 2005, 6, 127
5. Bland, N. D.; Wang, C.; Tallman, C.; Gustafson, A. E.; Wang, Z.; Ashton, T. D.; Ochiana, S. O.; McAllister, G.; Cotter, K.; Fang, A. P.; Gechijian, L.; Garceau, N.; Gangurde, R.; Ortenberg, R.; Ondrechen, M. J.; Campbell, R. K.; Pollastri, M. P. Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness J. Med. Chem. 2011, 54, 8188-8194
6. Ochiana, S. O.; Pandarinath, V.; Wang, Z.; Kapoor, R.; Ondrechen, M. J.; Ruben, L.; Pollastri, M. P. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing Eur. J. Med. Chem. 2012, 62, 777-784
7. Diaz-Gonzalez, R.; Kuhlmann, F. M.; Galan-Rodriguez, C.; Madeira da Silva, L.; Saldivia, M.; Karver, C. E.; Rodriguez, A.; Beverley, S. M.; Navarro, M.; Pollastri, M. P. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing PLoS Negl. Trop. Dis. 2011, 5, e1297
8. de Koning, H. P.; Gould, M. K.; Sterk, G. J.; Tenor, H.; Kunz, S.; Luginbuehl, E.; Seebeck, T. Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets J. Infect. Dis. 2012, 206, 229-237
9. Beghyn, T. B.; Charton, J.; Leroux, F.; Laconde, G.; Bourin, A.; Cos, P.; Maes, L.; Deprez, B. Drug to genome to drug: discovery of new antiplasmodial compounds J. Med. Chem. 2011, 54, 3222-3240
10. Nwaka, S.; Hudson, A. Innovative lead discovery strategies for tropical diseases Nature Rev. Drug Discovery 2006, 5, 941-955
11. Chahrour, O.; Cairns, D.; Omran, Z. Small molecule kinase inhibitors as anti-cancer therapeutics Mini-Rev. Med. Chem. 2012, 12, 399-411
12. Page, T. H.; Smolinska, M.; Gillespie, J.; Urbaniak, A. M.; Foxwell, B. M. Tyrosine kinases and inflammatory signalling Curr. Mol. Med. 2009, 9, 69-85
13. Ito, K.; Caramori, G.; Adcock, I. M. Therapeutic Potential of Phosphatidylinositol 3-Kinase Inhibitors in Inflammatory Respiratory Disease J. Pharmacol. Exp. Ther. 2007, 321, 1-8
14. Louvet, C.; Szot, G. L.; Lang, J.; Lee, M. R.; Martinier, N.; Bollag, G.; Zhu, S.; Weiss, A.; Bluestone, J. A. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 18895-18900
15. Wagman, A. S.; Johnson, K. W.; Bussiere, D. E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes Curr. Pharm. Des. 2004, 10, 1105-1137
16. Chico, L. K.; Van Eldik, L. J.; Watterson, D. M. Targeting protein kinases in central nervous system disorders Nature Rev. Drug Discovery 2009, 8, 892-909
17. Natoli, C. Tyrosine Kinase Inhibitors Curr. Cancer Drug Targets 2010, 10, 462
18. Lackey, K. E. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor Curr. Top. Med. Chem. 2006, 6, 435-460
19. Johannessen, L. E.; Ringerike, T.; Molnes, J.; Madshus, I. H. Epidermal growth factor receptor efficiently activates mitogen-activated protein kinase in HeLa cells and Hep2 cells conditionally defective in clathrin-dependent endocytosis Exp. Cell Res. 2000, 260, 136-145
20. Naula, C.; Parsons, M.; Mottram, J. C. Protein kinases as drug targets in trypanosomes and Leishmania Biochim. Biophys. Acta 2005, 1754, 151-159
21. Oduor, R. O.; Ojo, K. K.; Williams, G. P.; Bertelli, F.; Mills, J.; Maes, L.; Pryde, D. C.; Parkinson, T.; Van Voorhis, W. C.; Holler, T. P. Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads PLoS Negl. Trop. Dis. 2011, 5, e1017
22. Nett, I. R.; Martin, D. M.; Miranda-Saavedra, D.; Lamont, D.; Barber, J. D.; Mehlert, A.; Ferguson, M. A. The phosphoproteome of bloodstream form Trypanonosoma brucei, causative agent of African sleeping sickness Mol. Cell Proteomics 2009, 8, 1527-1538
23. Nett, I. R.; Davidson, L.; Lamont, D.; Ferguson, M. A. Identification and specific localization of tyrosine-phosphorylated proteins in Trypanosoma brucei Eukaryotic Cell 2009, 8, 617-626
24. Katiyar, S.; Kufareva, I.; Behera, R.; Ogata, Y.; Pollastri, M. P.; Abagyan, R.; Mensa-Wilmot, K. Lapatinib-Binding Protein Kinases in the African Trypanosome: A General Method for Identification of Targets for Kinase-Directed Drugs in a Cell PLoS One 2013, 8, e56150
25. Slichenmyer, W. J.; Elliott, W. L.; Fry, D. W. CI-1033, a pan-erbB tyrosine kinase inhibitor Semin. Oncol. 2001, 28, 80-85
26. Xia, W.; Mullin, R. J.; Keith, B. R.; Liu, L. H.; Ma, H.; Rusnak, D. W.; Owens, G.; Alligood, K. J.; Spector, N. L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 2002, 21, 6255-6263
27. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res. 2004, 64, 4931-4941
28. Steverding, D. The transferrin receptor of Trypanosoma brucei Parasitol. Int. 2000, 48, 191-198
29. Subramanya, S.; Hardin, C. F.; Steverding, D.; Mensa-Wilmot, K. Glycosylphosphatidylinositol-specific phospholipase C regulates transferrin endocytosis in the African trypanosome Biochem. J. 2009, 417, 685-694
30. Subramanya, S.; Mensa-Wilmot, K. Diacylglycerol-stimulated endocytosis of transferrin in trypanosomatids is dependent on tyrosine kinase activity PLoS One 2010, 5, e8538
31. Behera, R.; Guyett, P.; Thomas, S.; Katiyar, S.; Ogata, Y.; Mensa-Wilmot, K.,unpublished results
32. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol. Cancer Ther. 2001, 1, 85-94
33. Petrov, K. G.; Zhang, Y. M.; Carter, M.; Cockerill, G. S.; Dickerson, S.; Gauthier, C. A.; Guo, Y.; Mook, R. A., Jr.; Rusnak, D. W.; Walker, A. L.; Wood, E. R.; Lackey, K. E. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series Bioorg. Med. Chem. Lett. 2006, 16, 4686-4691
34. Rusnak, D. W.; Affleck, K.; Cockerill, S. G.; Stubberfield, C.; Harris, R.; Page, M.; Smith, K. J.; Guntrip, S. B.; Carter, M. C.; Shaw, R. J.; Jowett, A.; Stables, J.; Topley, P.; Wood, E. R.; Brignola, P. S.; Kadwell, S. H.; Reep, B. R.; Mullin, R. J.; Alligood, K. J.; Keith, B. R.; Crosby, R. M.; Murray, D. M.; Knight, W. B.; Gilmer, T. M.; Lackey, K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res. 2001, 61, 7196-7203
35. Cai, X.; Zhai, H.-X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.-J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-Ethynylphenylamino)-7- methoxyquinazolin-6-yloxy)- N -hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer J. Med. Chem. 2010, 53, 2000-2009
36. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
37. Webster, P.; Fish, W. R. Endocytosis by African trypanosomes. II. Occurrence in different life-cycle stages and intracellular sorting Eur. J. Cell Biol. 1989, 49, 303-310
38. Hall, B.; Allen, C. L.; Goulding, D.; Field, M. C. Both of the Rab5 subfamily small GTPases of Trypanosoma brucei are essential and required for endocytosis Mol. Biochem. Parasitol. 2004, 138, 67-77
39. Hammarton, T. C. Cell cycle regulation in Trypanosoma brucei Mol. Biochem. Parasitol. 2007, 153, 1-8
40. Siegel, T. N.; Hekstra, D. R.; Cross, G. A. Analysis of the Trypanosoma brucei cell cycle by quantitative DAPI imaging Mol. Biochem. Parasitol. 2008, 160, 171-174
41. Hammarton, T. C.; Monnerat, S.; Mottram, J. C. Cytokinesis in trypanosomatids Curr. Opin. Microbiol. 2007, 10, 520-527
42. Mackey, Z. B.; Baca, A. M.; Mallari, J. P.; Apsel, B.; Shelat, A.; Hansell, E. J.; Chiang, P. K.; Wolff, B.; Guy, K. R.; Williams, J.; McKerrow, J. H. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei Chem. Biol. Drug Des. 2006, 67, 355-363
43. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes ACS Chem. Neurosci. 2010, 1, 420-434
44. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties ACS Chem. Neurosci. 2010, 1, 435-449
45. Iino, T.; Sasaki, Y.; Bamba, M.; Mitsuya, M.; Ohno, A.; Kamata, K.; Hosaka, H.; Maruki, H.; Futamura, M.; Yoshimoto, R.; Ohyama, S.; Sasaki, K.; Chiba, M.; Ohtake, N.; Nagata, Y.; Eiki, J.-i.; Nishimura, T. Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators Bioorg. Med. Chem. Lett. 2009, 19, 5531-5538
46. Mahboobi, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrids as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity J. Med. Chem. 2010, 53, 8546-8555
47. Hirumi, H.; Hirumi, K. Axenic culture of African trypanosome bloodstream forms Parasitol. Today. 1994, 10, 80-84
48. Ferrari, M.; Fornasiero, M. C.; Isetta, A. M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro J. Immunol. Methods 1990, 131, 165-172
49. Sykes, M. L.; Baell, J. B.; Kaiser, M.; Chatelain, E.; Moawad, S. R.; Ganame, D.; Ioset, J.-R.; Avery, V. M. Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign PLoS Negl. Trop. Dis. 2012, 6, e1896
50. Sokolova, A. Y.; Wyllie, S.; Patterson, S.; Oza, S. L.; Read, K. D.; Fairlamb, A. H. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis Antimicrob. Agents Chemother. 2010, 54, 2893-2900
51. Jacobs, R. T.; Nare, B.; Wring, S. A.; Orr, M. D.; Chen, D.; Sligar, J. M.; Jenks, M. X.; Noe, R. A.; Bowling, T. S.; Mercer, L. T.; Rewerts, C.; Gaukel, E.; Owens, J.; Parham, R.; Randolph, R.; Beaudet, B.; Bacchi, C. J.; Yarlett, N.; Plattner, J. J.; Freund, Y.; Ding, C.; Akama, T.; Zhang, Y. K.; Brun, R.; Kaiser, M.; Scandale, I.; Don, R. SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis PLoS Negl. Trop. Dis. 2011, 5, e1151